About Angioblast Systems
Angioblast Systems is a company based in New York (United States) founded in 2001 was acquired by Mesoblast in May 2010. The company has 46 employees as of December 31, 2022. Angioblast Systems operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
- Headquarter New York, United States
- Employees 46 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mesoblast, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Angioblast Systems
Detailed funding history for Angioblast Systems
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Angioblast Systems
Angioblast Systems has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Mesoblast.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
Locked | Locked | Locked |
Investor details for Angioblast Systems
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Angioblast Systems
Investment portfolio details for Angioblast Systems
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Angioblast Systems
Detailed financials for Angioblast Systems
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Angioblast Systems Comparisons
Peer comparison for Angioblast Systems
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Angioblast Systems
Angioblast Systems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
Detailed competitors of Angioblast Systems
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Angioblast Systems
Complete news archive for Angioblast Systems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Angioblast Systems
Angioblast Systems was founded in 2001.
Angioblast Systems is headquartered in New York, United States. It is registered at New York, New York, United States.
As of Dec 31, 2022, the latest employee count at Angioblast Systems is 46.
Angioblast Systems was founded in 2001 in New York, United States, within the biotechnology sector focused on cell therapies. Operations center on the development and commercialization of treatments for cardiovascular conditions, including the lead product Revascor, which consists of immunoselected mesenchymal precursor cells for end-stage chronic heart failure. The company was acquired by Mesoblast in May 2010, concluding its independent activities.
Angioblast Systems's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Angioblast Systems has 1 investor. Key investors include Mesoblast.